Akari Therapeutics plc ADS (NASDAQ: AKTX)
$3.61
+0.1100 ( +3.14% ) 16.6K
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Market Data
Open
$3.61
Previous close
$3.50
Volume
16.6K
Market cap
$43.91M
Day range
$3.51 - $3.73
52 week range
$1.08 - $5.50
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 35 | Jul 25, 2023 |
6-k | Quarterly Reports | 2 | Jul 19, 2023 |
6-k | Quarterly Reports | 2 | Jul 13, 2023 |
6-k | Quarterly Reports | 2 | Jul 11, 2023 |
6-k | Quarterly Reports | 2 | Jul 07, 2023 |
6-k | Quarterly Reports | 2 | Jul 06, 2023 |
6-k | Quarterly Reports | 2 | Jul 05, 2023 |